POD24 and POD36 after treatment of HCL with subcutaneous cladribine. (A) POD24. (B) POD36. Early progression of disease after 24 months (POD24) occurred in 33 patients and after 36 months (POD36) in 46 patients. Neither POD24 (HR, 1.43; 95% CI, 0.68-3.0221; P = .351) nor POD36 (HR, 1.10; 95% CI, 0.52-2.31; P = .803) was discriminative for OS.